BR112013009267A2 - formulações e métodos para atenuar a depressão respiratória induzida por overdose de opioides - Google Patents

formulações e métodos para atenuar a depressão respiratória induzida por overdose de opioides

Info

Publication number
BR112013009267A2
BR112013009267A2 BR112013009267A BR112013009267A BR112013009267A2 BR 112013009267 A2 BR112013009267 A2 BR 112013009267A2 BR 112013009267 A BR112013009267 A BR 112013009267A BR 112013009267 A BR112013009267 A BR 112013009267A BR 112013009267 A2 BR112013009267 A2 BR 112013009267A2
Authority
BR
Brazil
Prior art keywords
formulations
methods
respiratory depression
opioid overdose
induced respiratory
Prior art date
Application number
BR112013009267A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Lamson
Veeraindar Goli
Original Assignee
Alpharma Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals Llc filed Critical Alpharma Pharmaceuticals Llc
Publication of BR112013009267A2 publication Critical patent/BR112013009267A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013009267A 2010-10-26 2011-10-25 formulações e métodos para atenuar a depressão respiratória induzida por overdose de opioides BR112013009267A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
BR112013009267A2 true BR112013009267A2 (pt) 2016-07-26

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009267A BR112013009267A2 (pt) 2010-10-26 2011-10-25 formulações e métodos para atenuar a depressão respiratória induzida por overdose de opioides

Country Status (14)

Country Link
US (3) US20140030343A1 (enExample)
EP (1) EP2632442A2 (enExample)
JP (1) JP2013540807A (enExample)
KR (3) KR20170102571A (enExample)
CN (1) CN103189055A (enExample)
AU (1) AU2011322147A1 (enExample)
BR (1) BR112013009267A2 (enExample)
CA (1) CA2814230A1 (enExample)
IL (1) IL225966A0 (enExample)
MX (1) MX2013003832A (enExample)
RU (1) RU2541159C2 (enExample)
SG (1) SG189234A1 (enExample)
WO (1) WO2012056402A2 (enExample)
ZA (1) ZA201302363B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
WO2012056402A2 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
JP2014504630A (ja) * 2011-02-02 2014-02-24 アルファーマ ファーマシューティカルズ エルエルシー オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3085348A1 (en) 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
JP2021526507A (ja) 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
US10517841B1 (en) * 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US20240100120A1 (en) * 2019-10-11 2024-03-28 Board Of Regents, The University Of Taxas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
KR20240101622A (ko) * 2021-11-02 2024-07-02 에날레어 테라퓨틱스 인크. 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326794T3 (es) * 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
EP1694386B1 (en) * 2003-12-05 2017-05-03 CareFusion 303, Inc. Patient-controlled analgesia with patient monitoring system
CN101321686A (zh) 2005-10-07 2008-12-10 佛罗里达大学研究基金会有限公司 用于多路信号传递和光编码的多组分纳米颗粒
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
US20090131466A1 (en) * 2007-09-04 2009-05-21 Alpharma, Inc. Pharmaceutical Compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2009278007B2 (en) 2008-07-31 2015-08-27 Alma Mater Studiorum - Universita' Di Bologna Active particles for bio-analytical applications and methods for their preparation
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
WO2012056402A2 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Also Published As

Publication number Publication date
US20140030343A1 (en) 2014-01-30
CA2814230A1 (en) 2012-05-03
ZA201302363B (en) 2014-06-25
WO2012056402A3 (en) 2012-10-04
KR20130097211A (ko) 2013-09-02
KR20160017668A (ko) 2016-02-16
IL225966A0 (en) 2013-06-27
JP2013540807A (ja) 2013-11-07
RU2541159C2 (ru) 2015-02-10
KR20170102571A (ko) 2017-09-11
EP2632442A2 (en) 2013-09-04
AU2011322147A1 (en) 2013-04-18
WO2012056402A2 (en) 2012-05-03
RU2013117274A (ru) 2014-12-10
CN103189055A (zh) 2013-07-03
US20170367987A1 (en) 2017-12-28
SG189234A1 (en) 2013-05-31
US20160045449A1 (en) 2016-02-18
MX2013003832A (es) 2013-10-01

Similar Documents

Publication Publication Date Title
BR112013009267A2 (pt) formulações e métodos para atenuar a depressão respiratória induzida por overdose de opioides
ZA201401526B (en) Method and formulation for inhalation
IL229409A0 (en) Intravenous pharmaceutical dosage forms containing naloxone
GB201400213D0 (en) Methods and systems for assuring compliance
IL227383A0 (en) Extended-release oral dosage forms containing tsucitinib
ZA201304406B (en) Inhalator
AU342595S (en) Inhaler device
EP2521584A4 (en) INHALATION DEVICE AND METHOD THEREFOR
BR112013025738A2 (pt) dispositivo dental para melhoria da respiração
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
PL2542285T3 (pl) Inhalator
GB2525835B (en) Pharmaceutical agent
LT2672846T (lt) Inhaliavimo įrenginys
IL233127A0 (en) A pharmaceutical preparation that includes brexpiprazole and modified beta-cyclodextrin
GB201200525D0 (en) An inhalable medicament
PL2536412T3 (pl) Wziewna kompozycja farmaceutyczna
IL232944A0 (en) Formulation for nasal administration
AU2011903839A0 (en) Inhalation device and method
GB201108234D0 (en) Pharmaceutical agent
AU2011903049A0 (en) Method and formulation for inhalation
AU2011905283A0 (en) Respiratory Device
AU333535S (en) Respiratory device
AU2011900385A0 (en) Animal restraint device

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]